T1	PROC 46 93	Estudio para evaluar la eficacia y la seguridad
T2	CHEM 97 108	mirikizumab
#1	AnnotatorNotes T2	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	DISO 126 145	enfermedad de Crohn
#2	AnnotatorNotes T3	C0010346; Crohn Disease; Disease or Syndrome
T4	PROC 175 276	Estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento doble, comparativo con un placebo
T5	PROC 282 293	tratamiento
#3	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	PROC 307 324	re-aleatorización
T7	PROC 330 364	evaluar la eficacia y la seguridad
#4	AnnotatorNotes T7	C0511730; Identify product efficacy and safety issues; Health Care Activity
T8	DISO 397 416	enfermedad de Crohn
#5	AnnotatorNotes T8	C0010346; Crohn Disease; Disease or Syndrome
T9	DISO 467 486	Enfermedad de Crohn
#6	AnnotatorNotes T9	C0010346; Crohn Disease; Disease or Syndrome
T10	DISO 513 532	Enfermedad de Crohn
#7	AnnotatorNotes T10	C0010346; Crohn Disease; Disease or Syndrome
T11	PROC 588 599	Diagnóstico
#8	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	DISO 603 605	EC
#9	AnnotatorNotes T12	C0010346; Crohn Disease; Disease or Syndrome
T13	PROC 652 663	Diagnóstico
#10	AnnotatorNotes T13	C0011900; Diagnosis; Diagnostic Procedure
T14	DISO 678 680	EC
#11	AnnotatorNotes T14	C0010346; Crohn Disease; Disease or Syndrome
T15	DISO 780 795	dolor abdominal
#12	AnnotatorNotes T15	C0000737; Abdominal Pain; Sign or Symptom
T16	DISO 816 828	Intolerancia
#13	AnnotatorNotes T16	C0277585; Intolerance to drug; Pathologic Function
T17	PROC 893 929	tratamiento convencional o biológico
T18	DISO 938 940	EC
#14	AnnotatorNotes T18	C0010346; Crohn Disease; Disease or Syndrome
T19	PROC 1001 1024	medidas anticonceptivas
T20	PROC 1081 1092	diagnóstico
#15	AnnotatorNotes T20	C0011900; Diagnosis; Diagnostic Procedure
T21	DISO 1096 1112	colitis ulcerosa
#16	AnnotatorNotes T21	C0009324; Ulcerative Colitis; Disease or Syndrome
T22	DISO 1114 1163	enfermedad inflamatoria intestinal inclasificable
T23	DISO 1165 1168	EII
#17	AnnotatorNotes T23	C0021390; Inflammatory Bowel Diseases; Disease or Syndrome
T24	DISO 1200 1221	colitis indeterminada
#18	AnnotatorNotes T24	C0341332; Indeterminate colitis; Disease or Syndrome
T25	DISO 1225 1253	absceso abdominal o perianal
T26	ANAT 1245 1253	perianal
#19	AnnotatorNotes T26	C0442158; Perianal; Body Location or Region
T27	DISO 1256 1284	síndrome del intestino corto
#20	AnnotatorNotes T27	C0036992; Short Bowel Syndrome; Disease or Syndrome
T28	ANAT 1301 1307	estoma
#21	AnnotatorNotes T28	C1955856; Surgical Stoma; Anatomical Structure
T29	PROC 1310 1317	ostomía
#22	AnnotatorNotes T29	C0029473; Ostomy; Therapeutic or Preventive Procedure
T30	PROC 1340 1360	resección intestinal
#23	AnnotatorNotes T30	C1096244; Intestinal resection; Therapeutic or Preventive Procedure
T31	PROC 1446 1476	cirugía intra o extraabdominal
T32	CHEM 1578 1599	anticuerpo monoclonal
#25	AnnotatorNotes T32	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T33	CHEM 368 379	mirikizumab
#26	AnnotatorNotes T33	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T34	ANAT 786 795	abdominal
#27	AnnotatorNotes T34	C0000726; Abdomen; Body Location or Region | C1281594; Entire abdomen; Body Part, Organ, or Organ Component
T35	ANAT 1138 1148	intestinal
#28	AnnotatorNotes T35	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T36	ANAT 1233 1242	abdominal
#29	AnnotatorNotes T36	C0000726; Abdomen; Body Location or Region | C1281594; Entire abdomen; Body Part, Organ, or Organ Component
T37	ANAT 1269 1278	intestino
#30	AnnotatorNotes T37	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T38	ANAT 1350 1360	intestinal
#31	AnnotatorNotes T38	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T39	CHEM 1614 1619	IL-23
#32	AnnotatorNotes T39	C0963088; interleukin-23; Amino Acid, Peptide, or Protein · Biologically Active Substance
T40	Date 13 17	2018
T41	LIVB 112 121	pacientes
#33	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Neg_cue 303 306	sin
T43	LIVB 383 392	pacientes
#34	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	Duration 606 622	al menos 3 meses
T45	LIVB 948 955	mujeres
#35	AnnotatorNotes T45	C0043210; Woman; Population Group
T46	Date 1064 1080	en la actualidad
T47	Duration 1381 1392	los 6 meses
T48	Duration 1497 1508	los 3 meses
T50	PHYS 735 747	deposiciones
#36	AnnotatorNotes T50	C0011135; Defecation; Organism Function
A1	Assertion T6 Negated
A2	Status T32 History_of
A3	Status T30 History_of
A4	Status T31 History_of
#37	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#38	AnnotatorNotes T4	C0282461; Phase 3 Clinical Trials; Research Activity + C1096776; Multicenter Study; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product
#39	AnnotatorNotes T17	C2945704; Conventional Treatment; Therapeutic or Preventive Procedure + C1531518; Biological treatment; Therapeutic or Preventive Procedure  
#40	AnnotatorNotes T19	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
#41	AnnotatorNotes T22	C4268603; Colonic inflammatory bowel disease  unclassified (IBDU); Disease or Syndrome
#42	AnnotatorNotes T25	C0031019; Perianal abscess; Disease or Syndrome + C0243001; Abdominal Abscess; Disease or Syndrome
#24	AnnotatorNotes T46	C0521116; Current (present time); Temporal Concept 
#43	AnnotatorNotes T31	C0198482; Operation on abdominal region; Therapeutic or Preventive Procedure
T49	Observation 717 747	frecuencia de las deposiciones
#44	AnnotatorNotes T49	C0426642; Frequency of bowel action; Finding
R1	Experiences Arg1:T41 Arg2:T2	
R2	Experiences Arg1:T41 Arg2:T3	
T51	Quantifier_or_Qualifier 146 152	activa
#45	AnnotatorNotes T51	C0679217; Active State; Idea or Concept
R3	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T51	
T52	Quantifier_or_Qualifier 417 423	activa
#46	AnnotatorNotes T52	C0679217; Active State; Idea or Concept
R4	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T52	
T53	Quantifier_or_Qualifier 533 539	activa
#47	AnnotatorNotes T53	C0679217; Active State; Idea or Concept
R5	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T53	
T54	Quantifier_or_Qualifier 294 300	activo
#48	AnnotatorNotes T54	C0679217; Active State; Idea or Concept
R6	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T54	
R7	Negation Arg1:T42 Arg2:T6	
R8	Experiences Arg1:T43 Arg2:T33	
R9	Experiences Arg1:T43 Arg2:T5	
R10	Experiences Arg1:T43 Arg2:T8	
T55	Quantifier_or_Qualifier 427 443	moderada a grave
#49	AnnotatorNotes T55	C1299393; Moderate to severe; Qualitative Concept
R11	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T55	
T56	Quantifier_or_Qualifier 543 559	moderada a grave
#50	AnnotatorNotes T56	C1299393; Moderate to severe; Qualitative Concept
R12	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T56	
R13	Has_Duration_or_Interval Arg1:T12 Arg2:T44	
T57	CONC 633 648	período inicial
#51	AnnotatorNotes T57	C1442488; Baseline; Quantitative Concept (?) | C4684789; Study Start; Temporal Concept (?)
R14	Before Arg1:T12 Arg2:T57	
R15	Before Arg1:T11 Arg2:T57	
T58	Quantifier_or_Qualifier 681 697	moderada a grave
#52	AnnotatorNotes T58	C1299393; Moderate to severe; Qualitative Concept
R16	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T58	
T59	PROC 806 812	SES-CD
#53	AnnotatorNotes T59	C5549856; Assessment using Simple Endoscopic Score for Crohn's Disease; Health Care Activity
R18	Location_of Arg1:T34 Arg2:T15	
R20	Overlap Arg1:T14 Arg2:T15	
R22	Causes Arg1:T17 Arg2:T16	
T60	Observation 830 850	pérdida de respuesta
#54	AnnotatorNotes T60	C5400193; Loss of therapeutic response; Finding
R23	Overlap Arg1:T60 Arg2:T17	
T61	Observation 853 875	respuesta insuficiente
#55	AnnotatorNotes T61	C1320680; Poor response to treatment; Finding
R24	Overlap Arg1:T61 Arg2:T17	
R25	Overlap Arg1:T60 Arg2:T18	
R26	Overlap Arg1:T61 Arg2:T18	
R27	Experiences Arg1:T45 Arg2:T19	
R28	Overlap Arg1:T20 Arg2:T46	
R29	Overlap Arg1:T21 Arg2:T46	
R30	Location_of Arg1:T35 Arg2:T22	
R31	Location_of Arg1:T35 Arg2:T23	
R32	Overlap Arg1:T22 Arg2:T46	
R33	Overlap Arg1:T24 Arg2:T46	
R34	Overlap Arg1:T25 Arg2:T46	
R35	Location_of Arg1:T36 Arg2:T25	
R36	Location_of Arg1:T26 Arg2:T25	
R37	Location_of Arg1:T37 Arg2:T27	
R38	Overlap Arg1:T27 Arg2:T46	
R39	Location_of Arg1:T38 Arg2:T30	
R40	Overlap Arg1:T30 Arg2:T47	
T62	CONC 1407 1422	período inicial
#56	AnnotatorNotes T62	C1442488; Baseline; Quantitative Concept (?) | C4684789; Study Start; Temporal Concept (?)
R41	Before Arg1:T30 Arg2:T62	
R42	Before Arg1:T31 Arg2:T62	
R43	Overlap Arg1:T31 Arg2:T48	
R19	Overlap Arg1:T16 Arg2:T18	
R21	Overlap Arg1:T23 Arg2:T46	
T63	Quantifier_or_Qualifier 1600 1619	dirigido a la IL-23
R44	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T63	
A5	Experiencer T45 Patient
A6	Experiencer T41 Patient
A7	Experiencer T43 Patient
